home / stock / bovnf / bovnf quote
Last: | $4.70 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $4.70 |
High: | $0 |
Low: | $0 |
Volume: | 14 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.7 | $0 | $4.7 | $0 | $0 | 14 | 02-08-2023 |
$4.7 | $0 | $4.7 | $0 | $0 | 80 | 01-24-2023 |
$4.7 | $4.7 | $4.7 | $4.7 | $4.7 | 908 | 07-29-2022 |
$5.49 | $5.49 | $5.49 | $5.49 | $5.49 | 100 | 12-21-2021 |
$5.25 | $5.25 | $5.25 | $5.25 | $5.25 | 1,000 | 12-16-2021 |
$5.25 | $5.25 | $5.25 | $5.25 | $5.25 | 1,000 | 12-10-2021 |
$5.38 | $5.38 | $5.38 | $5.38 | $5.38 | 3,000 | 09-07-2021 |
$6.84 | $6.84 | $6.84 | $6.84 | $6.84 | 600 | 06-29-2021 |
$5.6 | $5.6 | $5.6 | $5.6 | $5.6 | 100 | 03-18-2021 |
$0.2 | $0.2 | $0.2 | $0.2 | $0.2 | 2,500 | 12-09-2020 |
$0.1847 | $0.1847 | $0.1847 | $0.1847 | $0.1847 | 25,000 | 07-21-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 01-31-2020 |
News, Short Squeeze, Breakout and More Instantly...
Bioinvent Ab Company Name:
BOVNF Stock Symbol:
OTCMKTS Market:
The two poster presentations will report - first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm combination data from the Phase 1/2a study with BI-1206 in combin...
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV) "During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahe...
LUND, SWEDEN / ACCESSWIRE / April 4, 2024 / BioInvent International AB (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2023 has been pu...